Ultrasound Shown to be Superior Diagnostic Compared to Mammography in Women Ages 30-39
Ramucirumab Improves Overall Survival, Progression-Free Survival in Phase III Trial
New Phase III Follow-Up Data of Yervoy Trial Shows 19 Percent Survival at Four Years
Two Phase II Trials Display Ramucirumab Potential Efficacy
Gene Variant Associated With 44 Percent Cancer Risk Reduction
Five-Fold Increase in Chordoma Risk Linked to Common Gene Variant
HCT Survivors More Likely To Show Heart Disease Risk Factors
PV-10 Produces 51 Percent Response Rate in Phase II Trial
Folic Acid, Vitamins B6 and 12 Do Not Affect Colorectal Adenoma Risk
Three Studies Test Oncotype DX In Breast and Colon Cancers
NCI-Approved CTEP Trials For the Month of October
FDA Approves Abraxane And Alimta for NSCLC
Trending Stories
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - Oncologist Rachna Shroff endows award to outlast her cancer diagnosis
“Because of my health, I have a profound desire to see this endowment come to fruition now” - Michael Caputo appointed to President’s Cancer Panel
The cancer survivor and political operative says his appointment signals Trump’s interest in cancer, survivorship - KRAS pioneer and Stephenson Prize winner Frank McCormick aims to prevent all KRAS cancers with a pill
- From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - Letai: MCEDs are a “great ideal”—alas, the data don’t support widespread use
“Projecting sub-ideal tests across a large population can cause harm,” Letai says, as Galleri cruises toward FDA approval
